Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | F7 | P08709 | 2/20 | 0.35 |
| ▸ | USP14 | P54578 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7153753 | 1.00 | L3MBTL1 (0.44) | L3MBTL1F10LMNATSHRPOLB | |
| SCHEMBL7151893 | 0.86 | F10 (0.57) | F10F7 | |
| Hydrochloric Acid SCHEMBL6876133 | 0.86 | F10 (0.56) | L3MBTL1F10F7 | |
| SCHEMBL7149887 | 0.84 | F10 (0.43) | L3MBTL1F10LMNATDP1F7 | |
| SCHEMBL6872185 | 0.81 | F10 (0.42) | F10F7 | |
| SCHEMBL6874667 | 0.80 | F10 (0.40) | F10F7 | |
| SCHEMBL6866547 | 0.80 | F10 (0.65) | F10F7 | |
| SCHEMBL7147090 | 0.80 | F10 (0.53) | F10LMNAF7USP14 | |
| SCHEMBL6871497 | 0.80 | F10 (0.49) | F10F7USP14 | |
| SCHEMBL6871337 | 0.80 | F10 (0.51) | F10LMNAF7USP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642386-B2 | Having alkoxy, halo and piperidin-4-yl substituents; water soluble; coagulation factors Xa and IXa, thrombin induced factor VIIa and tissue factor inhibitors | HOFFMANN-LA ROCHE INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030166683-A1 | N-(4-CARBAMIMIDOYL-PHENYL)-GLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166683-A1 | N-(4-CARBAMIMIDOYL-PHENYL)-GLYCINE DERIVATIVES | F2, F12, F5 | L3MBTL1 2843/4885F10 7/4885LMNA 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.